200 related articles for article (PubMed ID: 37034659)
1. Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosis.
Prapiadou S; Živković L; Thorand B; George MJ; van der Laan SW; Malik R; Herder C; Koenig W; Ueland T; Kleveland O; Aukrust P; Gullestad L; Bernhagen J; Pasterkamp G; Peters A; Hingorani AD; Rosand J; Dichgans M; Anderson CD; Georgakis MK
medRxiv; 2023 Mar; ():. PubMed ID: 37034659
[TBL] [Abstract][Full Text] [Related]
2. Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis.
Prapiadou S; Živković L; Thorand B; George MJ; van der Laan SW; Malik R; Herder C; Koenig W; Ueland T; Kleveland O; Aukrust P; Gullestad L; Bernhagen J; Pasterkamp G; Peters A; Hingorani AD; Rosand J; Dichgans M; Anderson CD; Georgakis MK
Circulation; 2024 Feb; 149(9):669-683. PubMed ID: 38152968
[TBL] [Abstract][Full Text] [Related]
3. Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study.
Levin MG; Klarin D; Assimes TL; Freiberg MS; Ingelsson E; Lynch J; Natarajan P; O'Donnell C; Rader DJ; Tsao PS; Chang KM; Voight BF; Damrauer SM;
JAMA Netw Open; 2021 Jan; 4(1):e2034461. PubMed ID: 33464320
[TBL] [Abstract][Full Text] [Related]
4. Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups.
Georgakis MK; Malik R; Richardson TG; Howson JMM; Anderson CD; Burgess S; Hovingh GK; Dichgans M; Gill D
BMC Med; 2022 Aug; 20(1):245. PubMed ID: 35948913
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study.
Nolde M; Alayash Z; Reckelkamm SL; Kocher T; Ehmke B; Holtfreter B; Baurecht H; Georgakis MK; Baumeister SE
Front Immunol; 2023; 14():1160148. PubMed ID: 37342352
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.
Eid RE; Rao DA; Zhou J; Lo SF; Ranjbaran H; Gallo A; Sokol SI; Pfau S; Pober JS; Tellides G
Circulation; 2009 Mar; 119(10):1424-32. PubMed ID: 19255340
[TBL] [Abstract][Full Text] [Related]
7. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Downregulated Interleukin-6 Signaling for the Treatment of Chronic Pain: A Mendelian Randomization Study.
Bi Y; Zhu Y; Tang S
J Pain Res; 2023; 16():4317-4328. PubMed ID: 38145035
[TBL] [Abstract][Full Text] [Related]
9. Leveraging genetic data to investigate the effects of interleukin-6 receptor signalling on levels of 40 circulating cytokines.
Rahman RP; McEwan L; Ryan DK; Gill D
Br J Clin Pharmacol; 2022 Mar; 88(3):1373-1378. PubMed ID: 34506050
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of genetically proxied interleukin-5 inhibition: A mendelian randomization study.
Alton P; Hughes DM; Zhao SS
Respir Investig; 2023 Mar; 61(2):149-152. PubMed ID: 36682083
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis.
Wang K; Shi M; Huang C; Fan B; Luk AOY; Kong APS; Ma RCW; Chan JCN; Chow E
Cardiovasc Diabetol; 2022 Sep; 21(1):192. PubMed ID: 36151532
[TBL] [Abstract][Full Text] [Related]
12. Association Between Genetically Proxied Lipid-Lowering Drug Targets and Renal Cell Carcinoma: A Mendelian Randomization Study.
Liu L; Sheng C; Lyu Z; Dai H; Chen K
Front Nutr; 2021; 8():755834. PubMed ID: 34712689
[TBL] [Abstract][Full Text] [Related]
13. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.
De Marchis GM; Dittrich TD; Malik R; Zietz AV; Kriemler LF; Ference BA; Dichgans M; Georgakis MK
Atherosclerosis; 2022 Nov; 361():41-46. PubMed ID: 36244797
[TBL] [Abstract][Full Text] [Related]
14. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
15. Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis.
Georgakis MK; Malik R; Burgess S; Dichgans M
J Am Heart Assoc; 2022 Jan; 11(1):e023277. PubMed ID: 34927447
[TBL] [Abstract][Full Text] [Related]
16. Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease.
Sjaarda J; Gerstein H; Chong M; Yusuf S; Meyre D; Anand SS; Hess S; Paré G
J Am Coll Cardiol; 2018 Jul; 72(3):300-310. PubMed ID: 30012324
[TBL] [Abstract][Full Text] [Related]
17. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
[TBL] [Abstract][Full Text] [Related]
18. Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two-sample Mendelian randomization study.
Yuan S; Lin A; He QQ; Burgess S; Larsson SC
Int J Cardiol; 2020 Aug; 313():99-104. PubMed ID: 32223966
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R.
Cupido AJ; Asselbergs FW; Natarajan P; ; Ridker PM; Hovingh GK; Schmidt AF
Br J Clin Pharmacol; 2022 Jun; 88(6):2875-2884. PubMed ID: 34931349
[TBL] [Abstract][Full Text] [Related]
20. Novel Drug Targets for Ischemic Stroke Identified Through Mendelian Randomization Analysis of the Blood Proteome.
Chong M; Sjaarda J; Pigeyre M; Mohammadi-Shemirani P; Lali R; Shoamanesh A; Gerstein HC; Paré G
Circulation; 2019 Sep; 140(10):819-830. PubMed ID: 31208196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
